China's Drug Re-registration Aims To Eliminate Inferior Drugs
This article was originally published in PharmAsia News
Executive Summary
Zhang Wei, Director of China's State FDA, wants to remove drugs from the market that are no longer fit for manufacturing, low-quality and high-risk by implementing a re-registration process